www.rxwiki.com
Nearly all postmenopausal women with early-stage, HR+ breast cancer are treated with aromatase inhibitors. But these drugs can significantly compromise bone health and up the risk of fractures.
For this reason, high-risk patients are often prescribed the osteoporosis drug denosumab (brand name Prolia) to reduce their risk of fractures.
But denosumab may have another benefit, a new study found. Adding denosumab to aromatase inhibitor therapy may improve disease-free survival in postmenopausal women with early-stage, HR+ breast cancer.
Because denosumab is currently only approved by the US Food and Drug Administration (FDA) for breast cancer patients who are at high risk for fractures, the drug is typically only added to the treatment regimens of patients with established osteoporosis. Osteoporosis a condition that causes the bones to become weak and brittle.
![](https://i.ytimg.com/vi/jtWYYbUUSEs/mqdefault.jpg)